INTRODUCTION
T he antiphospholipid syndrome (APS) is an autoimmune condition characterized by recurrent thromboembolic phenomenon and pregnancy morbidities associated with fetal loss. Antiphospholipid (APL) antibodies (APLAs) are defined as a group of antibodies directed against epitopes on plasma proteins that are uncovered by binding of these proteins to anionic phospholipids on plasma membranes. The most commonly used tests, to detect APL, include lupus anticoagulant (LAC), anticardiolipin (ACL) antibodies, and anti-β 2 -glycoprotein I (GPI) antibodies. [1] An accurate data on the incidence of the true prevalence of the APS is unavailable due to the paucity of guidelines and disease detection criteria. The prevalence of the disease among the different patient populations in India has been reported to be between 25.5% and 51.5%. [2] The Indian data antiphosophatidyl-inositol and antiprothrombin. Of clinical importance amidst these are LAC, ACL and anti-β 2 -GPI. The ways of detecting these antibodies include direct assessment of the levels of the antibodies in the blood or the effect of the antibodies on clotting. The tests most frequently employed in LA testing are the activated partial thromboplastin time, the dilute Russell's viper venom time and the kaolin clotting time while the ACL assay is performed using the ELISA test. [6] 
ANTIPHOSPHOLIPID, ANTIPHOSPHOLIPID SYNDROME IN PAEDIATRIC POPULATION
Studies show that the pediatric population has an increased incidence of APLAs, and most of them could be asymptomatic. The reason attributed towards the development of these antibodies is the presence of frequent infections in childhood. [7] APL positivity should be confirmed twice in children since the postinfectious elevation of APL levels may only be transient. There have been reports showing increased levels of β 2 -GPI in cases of atopic dermatitis without any increase in the risk for APS. A meta-analysis of the published studies that investigated the prevalence and clinical significance of APL in pediatric systemic lupus erythematosus (SLE) showed a global prevalence of 44% for ACL, 40% for antiβ 2 -GPI and 22% for LAC. [8] In the study by Makhija et al. in 2008 the prevalence of APS was 25% of the 36 pediatric patients with stroke being the commonest presentation. [9] In 2001 Singh et al. showed that the most common presentation in young patients was myocardial infarction and stroke with 18.18% patients in the stroke subgroup and 4.16% patients in myocardial infarction subgroup had raised ACL titers. [10] ANTIPHOSPHOLIPID ANTIBODY SYNDROME Antiphospholipid syndrome is an autoimmune disorder with a thrombophilic tendency leading to recurrent thrombosis and pregnancy morbidity with fetal loss. Based on whether there is an underlying cause or not it can be divided into primary and secondary form. The primary form of this condition is not associated with any underlying disorder while the secondary form is generally associated with an underlying SLE.
The onset has been reported in children as young as 8 months. Studies have shown that patients with associated rheumatic disease were older and had a higher frequency of venous thrombotic events associated with hematologic and skin manifestations. A female predilection exists for secondary APS most likely due to the increased incidence of SLE in them.
PATHOGENESIS
The formation of the clot in APS can be explained by a two-hit hypothesis which triggers the process of clotting. Experimental models as well as in clinical observations demonstrated that infections, surgical intervention or other procoagulant factor may precipitate the thrombosis. [10] [11] [12] Singh et al. demonstrated the presence of activated platelets have several altered functions in the in vivo and in vitro studies. The literature and evidences suggest the role of altered platelet function to be important irrespective of the triggering factors. Detailed study on the pathogenic mechanism, if possible using individualized antithrombotic strategies will help to elaborate on the pathogenetic mechanisms of APS. [13] 
CLINICAL FEATURES
Noncutaneous features include thrombotic events in the form of pulmonary thromboemolism, strokes, retinal vein and artery thrombosis. Hematological abnormalities include thrombocytopenia, autoimmune hemolytic anemia and leukocytopenia. Neurologic manifestations include headaches, seizures and chorea.
Thrombosis has been attributed as the major clinical feature of APS with recurrence of thrombosis occurring in almost 20% of patients. [14] A very small group of people with APLAs develop multiple clots in different organ systems throughout the body within a matter of days. This is called catastrophic APLA syndrome. [15] Antiphospholipid syndrome manifesting in children with only cutaneous manifestation is generally rare. Cutaneous manifestations include gangrene, ulceration, livedo reticularis, thrombophlebitis, necrotic purpura, Raynaud phenomenon, leukocytoclastic vasculitis, Degos-like ulceration and pyoderma gangrenosum like ulceration. Although Raynaud phenomenon and livedo reticularis represent the most common skin manifestation, each amounting to 6% of the affected patients, cutaneous necrosis was the sole manifestation in one report from India. [16] Sneddon syndrome, characterized by the triad of livedo reticularis, hypertension, and cerebrvascular disease is rare in children. However, there have been reports of the same in the past. [17] [18] [19] 
DIAGNOSIS
The diagnosis of this condition can be done using revised Saporro criteria which include at least one clinical criteria and one laboratory criteria.
MANAGEMENT
There is a paucity of data regarding the guidelines for the management of APS and most of the times it is extrapolated from the adult guidelines and recommendations. As reports suggest, most patients require international normalized ratio (INR) of 3-4 like that of adults to prevent recurrent events. [6] There were no reports of any adverse events experiences by the Canadian study group when they used anticoagulants for their patients. [3] However the safety of anticoagulants in children has not been studied adequately. Aspirin at low dose is used as prophylaxis in children with autoimmune diseases such as SLE along with APL. [6] Low molecular weight heparin and enoxaparin have been both used for the acute management of thromboembolic events. A study of 14 patients treated for active thrombosis and five treated prophylactically showed that low molecular weight heparin (LMWH) were at least as effective and safe as unfractionated heparin in pediatric patients immediately after a thrombotic event. [20] Albisetti and Andrew concluded that LMWH is an efficient and safe alternative to standard anticoagulation therapy with unfractionated heparin and oral anticoagulants for treatment and prevention of thromboembolic phenomenon in children of varying ages and with different underlying disorders. [21] Children with catastrophic APS are managed with intravenous anticoagulation and plasmapheresis. The long-term management of APS has been advised with oral warfarin. An intermediate intensity anticoagulation treatment with a target INR of 2.0-2.5 has been suggested in children with APS by Uysal et al. and Manco-Johnson and Nuss [22, 23] CONCLUSION Although the main clinical features of APS include noncutaneous manifestations with occasional cutaneous manifestation in children, it is worthwhile to have knowledge regarding the varied cutaneous features of this condition along with work up guidelines of these patients. Early suspicion of this condition based on the clinical characteristics will help in effective detection and management of these cases.
